Stock listing
RGNT Stock Price, News, Filings & Events — Regentis Biomaterials Ltd.
Selected listing: RGNT · AMEX · USD · US
This page tracks Regentis Biomaterials Ltd.'s RGNT:AMEX listing on AMEX in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following RGNT:AMEX. RGNT:AMEX is the stock-level entry point for investors researching Regentis Biomaterials Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Regentis Biomaterials Ltd. is a public company traded under the ticker RGNT in the American market. The company has a market capitalization of approximately $13.77 million. Regentis focuses on developing innovative biomaterials for medical applications.
- Ticker
- RGNT:AMEX
- Asset type
- Stock
- Market cap
- $13.3M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- AMEX
- Currency
- USD
Regentis Biomaterials Ltd. RGNT:AMEX stock context
This page tracks Regentis Biomaterials Ltd.'s RGNT:AMEX listing on AMEX in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following RGNT:AMEX. RGNT:AMEX is the stock-level entry point for investors researching Regentis Biomaterials Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Regentis Biomaterials Ltd. is a public company traded under the ticker RGNT in the American market. The company has a market capitalization of approximately $13.77 million. Regentis focuses on developing innovative biomaterials for medical applications.
Latest news from Regentis Biomaterials Ltd.
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
September 11, 2026
Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
July 16, 2026
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
June 17, 2026
Regentis Biomaterials (RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones
June 1, 2026
Regentis Biomaterials (RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant
May 29, 2026
Research Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. investor report
Review AI stock analysis and investor report context for RGNT:AMEX.
Regentis Biomaterials Ltd. company profile
View the public company page for Regentis Biomaterials Ltd. on 6ix.
Regentis Biomaterials Ltd. news
Read company news and market updates connected to Regentis Biomaterials Ltd..
Regentis Biomaterials Ltd. investor events
Find investor webinars, events, and replay context for Regentis Biomaterials Ltd..